the participants had reached a normal weight or resolved their weight-related health conditions after being on a weekly GLP-1 therapy, in this case either Ozempic (semaglutide) or Zepbound (tirzepatide)
In summary, the favourable effects of GLP-1MK-801 on glucose homeostasis seem to stem from both its incretin action and its weight-reducing effect
To gain access to the data, a request can be made to TriNetX ([email protected]), but costs might be incurred, and a data-sharing agreement would be necessary
References NCD Risk Factor Collaboration (NCD-RisC)
Key highlights Retatrutide is a next-generation weight loss medication that activates GLP-1, GIP, and glucagon receptors simultaneously to promote appetite suppression, improve metabolic health, and increase energy expenditure
We are not a pharmacy, clinic, or drug approval authority